Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Progressive Pulmonary Fibrosis: Where Are We Now?

  • Hyung Koo Kang (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Inje University College of Medicine) ;
  • Jin Woo Song (Department of Pulmonology and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2023.08.12
  • Accepted : 2023.12.04
  • Published : 2024.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Interstitial lung diseases (ILDs) are a diverse collection of lung disorders sharing similar features, such as inflammation and fibrosis. The diagnosis and management of ILD require a multidisciplinary approach using clinical, radiological, and pathological evaluation. Progressive pulmonary fibrosis (PPF) is a distinct form of progressive and fibrotic disease, occurring in ILD cases other than in idiopathic pulmonary fibrosis (IPF). It is defined based on clinical symptoms, lung function, and chest imaging, regardless of the underlying condition. The progression to PPF must be monitored through a combination of pulmonary function tests (forced vital capacity [FVC] and diffusing capacity of the lung for carbon monoxide), an assessment of symptoms, and computed tomography scans, with regular follow-up. Although the precise mechanisms of PPF remain unclear, there is evidence of shared pathogenetic mechanisms with IPF, contributing to similar disease behavior and worse prognosis compared to non-PPF ILD. Pharmacological treatment of PPF includes immunomodulatory agents to reduce inflammation and the use of antifibrotics to target progressive fibrosis. Nintedanib, a known antifibrotic agent, was found to be effective in slowing IPF progression and reducing the annual rate of decline in FVC among patients with PPF compared to placebos. Nonpharmacological treatment, including pulmonary rehabilitation, supplemental oxygen therapy, and vaccination, also play important roles in the management of PPF, leading to comprehensive care for patients with ILD. Although there is currently no cure for PPF, there are treatments that can help slow the progression of the disease and improve quality of life.

Keywords

Acknowledgement

This study was supported by grants from the Basic Science Research Program (NRF-2022R1A2B5B02001602) and the Bio & Medical Technology Development Program (NRF-2022M3A9E4082647) of the National Research Foundation of Korea (NRF) funded by the Ministry of Science & ICT, Republic of Korea, as well as by grants from the National Institute of Health research project (2021ER120701) and the Korea Environment Industry & Technology Institute through the Core Technology Development Project for Environmental Diseases Prevention and Management Program funded by the Korea Ministry of the Environment (RS-2022-KE002197), Republic of Korea.

References

  1. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias: this joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277-304. https://doi.org/10.1164/ajrccm.165.2.ats01
  2. Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008;63 Suppl 5:v1-58. https://doi.org/10.1136/thx.2008.101691
  3. Park SW, Baek AR, Lee HL, Jeong SW, Yang SH, Kim YH, et al. Korean guidelines for diagnosis and management of interstitial lung diseases: Part 1. Introduction. Tuberc Respir Dis (Seoul) 2019;82:269-76. https://doi.org/10.4046/trd.2018.0090
  4. Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med 2020;383:958-68. https://doi.org/10.1056/NEJMra2005230
  5. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188:733-48. https://doi.org/10.1164/rccm.201308-1483ST
  6. Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med 2018;378:1811-23. https://doi.org/10.1056/NEJMra1705751
  7. Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2022;205:e18-47. https://doi.org/10.1164/rccm.202202-0399ST
  8. Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ; IPF Consensus Working Group. What's in a name?: that which we call IPF, by any other name would act the same. Eur Respir J 2018;51:1800692.
  9. Rajan SK, Cottin V, Dhar R, Danoff S, Flaherty KR, Brown KK, et al. Progressive pulmonary fibrosis: an expert group consensus statement. Eur Respir J 2023;61:2103187.
  10. Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019;381:1718-27. https://doi.org/10.1056/NEJMoa1908681
  11. Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 2020;8:147-57. https://doi.org/10.1016/S2213-2600(19)30341-8
  12. Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med 2021;9:476-86. https://doi.org/10.1016/S2213-2600(20)30554-3
  13. Selman M, Pardo A. When things go wrong: exploring possible mechanisms driving the progressive fibrosis phenotype in interstitial lung diseases. Eur Respir J 2021;58:2004507.
  14. Richeldi L, Cottin V, du Bois RM, Selman M, Kimura T, Bailes Z, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS trials. Respir Med 2016;113:74-9. https://doi.org/10.1016/j.rmed.2016.02.001
  15. Idiopathic Pulmonary Fibrosis Clinical Research Network; Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012;366:1968-77. https://doi.org/10.1056/NEJMoa1113354
  16. Renzoni EA, Poletti V, Mackintosh JA. Disease pathology in fibrotic interstitial lung disease: is it all about usual interstitial pneumonia? Lancet 2021;398:1437-49. https://doi.org/10.1016/S0140-6736(21)01961-9
  17. Shah Gupta R, Koteci A, Morgan A, George PM, Quint JK. Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review. BMJ Open Respir Res 2023;10:e001291.
  18. Joung KI, Park H, Park S, Shin JY, Kim YH. Nationwide epidemiologic study for fibrosing interstitial lung disease (F-ILD) in South Korea: a population-based study. BMC Pulm Med 2023;23:98.
  19. Chandra D, Maini R, Hershberger DM. Cryptogenic organizing pneumonia. In: StatPearls. Treasure Island: StatPearls Publishing; 2023 [cited 2023 Dec 19]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507874.
  20. Cottin V, Si-Mohamed S, Diesler R, Bonniaud P, Valenzuela C. Pleuroparenchymal fibroelastosis. Curr Opin Pulm Med 2022;28:432-40. https://doi.org/10.1097/MCP.0000000000000907
  21. Ryerson CJ, Urbania TH, Richeldi L, Mooney JJ, Lee JS, Jones KD, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J 2013;42:750-7. https://doi.org/10.1183/09031936.00131912
  22. Yoo H, Hino T, Hwang J, Franks TJ, Han J, Im Y, et al. Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): evolving concept of CT findings, pathology and management. Eur J Radiol Open 2022;9:100419.
  23. Comarmond C, Crestani B, Tazi A, Hervier B, Adam-Marchand S, Nunes H, et al. Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature. Medicine (Baltimore) 2014;93:340-9. https://doi.org/10.1097/MD.0000000000000217
  24. Skeoch S, Weatherley N, Swift AJ, Oldroyd A, Johns C, Hayton C, et al. Drug-induced interstitial lung disease: a systematic review. J Clin Med 2018;7:356.
  25. Litow FK, Petsonk EL, Bohnker BK, Brodkin CA, Cowl CT, Guidotti TL, et al. Occupational interstitial lung diseases. J Occup Environ Med 2015;57:1250-4. https://doi.org/10.1097/JOM.0000000000000608
  26. Tazi A. Adult pulmonary Langerhans' cell histiocytosis. Eur Respir J 2006;27:1272-85. https://doi.org/10.1183/09031936.06.00024004
  27. Larsen BT, Smith ML, Elicker BM, Fernandez JM, de Morvil GA, Pereira CA, et al. Diagnostic approach to advanced fibrotic interstitial lung disease: bringing together clinical, radiologic, and histologic clues. Arch Pathol Lab Med 2017;141:901-15. https://doi.org/10.5858/arpa.2016-0299-SA
  28. Hambly N, Farooqi MM, Dvorkin-Gheva A, Donohoe K, Garlick K, Scallan C, et al. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. Eur Respir J 2022;60:2102571.
  29. Takei R, Brown KK, Yamano Y, Kataoka K, Yokoyama T, Matsuda T, et al. Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype. Respirology 2022;27:333-40. https://doi.org/10.1111/resp.14245
  30. Nasser M, Larrieu S, Si-Mohamed S, Ahmad K, Boussel L, Brevet M, et al. Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study). Eur Respir J 2021;57:2002718.
  31. Kwon BS, Choe J, Chae EJ, Hwang HS, Kim YG, Song JW. Progressive fibrosing interstitial lung disease: prevalence and clinical outcome. Respir Res 2021;22:282.
  32. Nashatyreva MS, Trofimenko IN, Chernyak BA, Avdeev SN. Pulmonary fibrosis and progressive pulmonary fibrosis in a prospective registry of interstitial lung diseases in Eastern Siberia. Life (Basel) 2023;13:212.
  33. Zhang T, Shen P, Duan C, Gao L. KL-6 as an immunological biomarker predicts the severity, progression, acute exacerbation, and poor outcomes of interstitial lung disease: a systematic review and meta-analysis. Front Immunol 2021;12:745233.
  34. Min B, Grant-Orser A, Johannson KA. Peripheral blood monocyte count and outcomes in patients with interstitial lung disease: a systematic review and meta-analysis. Eur Respir Rev 2023;32:230072.
  35. Inoue Y, Kaner RJ, Guiot J, Maher TM, Tomassetti S, Moiseev S, et al. Diagnostic and prognostic biomarkers for chronic fibrosing interstitial lung diseases with a progressive phenotype. Chest 2020;158:646-59. https://doi.org/10.1016/j.chest.2020.03.037
  36. Khor YH, Farooqi M, Hambly N, Kolb M, Ryerson CJ; Austin ILD Registry and CARE-PF Investigators. Patient characteristics and survival for progressive pulmonary fibrosis using different definitions. Am J Respir Crit Care Med 2023;207:102-5. https://doi.org/10.1164/rccm.202205-0910LE
  37. Brown KK, Martinez FJ, Walsh SL, Thannickal VJ, Prasse A, Schlenker-Herceg R, et al. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J 2020;55:2000085.
  38. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis: an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015;192:e3-19. https://doi.org/10.1164/rccm.201506-1063ST
  39. Flaherty KR, Wells AU, Cottin V, Devaraj A, Inoue Y, Richeldi L, et al. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. Eur Respir J 2022;59:2004538.
  40. Cottin V, Richeldi L, Rosas I, Otaola M, Song JW, Tomassetti S, et al. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. Respir Res 2021;22:84.
  41. Ghazipura M, Mammen MJ, Bissell BD, Macrea M, Herman DD, Hon SM, et al. Pirfenidone in progressive pulmonary fibrosis: a systematic review and meta-analysis. Ann Am Thorac Soc 2022;19:1030-9. https://doi.org/10.1513/AnnalsATS.202103-342OC
  42. Kolb MR, Flaherty KR. The justification for the progressive fibrotic phenotype. Curr Opin Pulm Med 2021;27:363-7. https://doi.org/10.1097/MCP.0000000000000803
  43. van den Bosch L, Luppi F, Ferrara G, Mura M. Immunomodulatory treatment of interstitial lung disease. Ther Adv Respir Dis 2022;16:17534666221117002.
  44. Baughman RP, Valeyre D, Korsten P, Mathioudakis AG, Wuyts WA, Wells A, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 2021;58:2004079.
  45. Hamblin M, Prosch H, Vasakova M. Diagnosis, course and management of hypersensitivity pneumonitis. Eur Respir Rev 2022;31:210169.
  46. King TE Jr, Lee JS. Cryptogenic organizing pneumonia. N Engl J Med 2022;386:1058-69. https://doi.org/10.1056/NEJMra2116777
  47. Ejima M, Okamoto T, Suzuki T, Anzai T, Takahashi K, Miyazaki Y. Efficacy of treatment with corticosteroids for fibrotic hypersensitivity pneumonitis: a propensity scorematched cohort analysis. BMC Pulm Med 2021;21:243.
  48. Vanthuyne M, Blockmans D, Westhovens R, Roufosse F, Cogan E, Coche E, et al. A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol 2007;25:287-92.
  49. Griffiths B, Miles S, Moss H, Robertson R, Veale D, Emery P. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 2002;29:2371-8.
  50. Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 2013;40:640-6. https://doi.org/10.3899/jrheum.121043
  51. Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016;4:708-19. https://doi.org/10.1016/S2213-2600(16)30152-7
  52. Fiddler CA, Simler N, Thillai M, Parfrey H. Use of mycophenolate mofetil and azathioprine for the treatment of chronic hypersensitivity pneumonitis: a single-centre experience. Clin Respir J 2019;13:791-4. https://doi.org/10.1111/crj.13086
  53. Boerner EB, Cuyas M, Theegarten D, Ohshimo S, Costabel U, Bonella F. Azathioprine for connective tissue disease-associated interstitial lung disease. Respiration 2020;99:628-36. https://doi.org/10.1159/000508540
  54. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54:3962-70. https://doi.org/10.1002/art.22204
  55. Terras Alexandre A, Martins N, Raimundo S, Melo N, Catetano Mota P, Novais E Bastos H, et al. Impact of azathioprine use in chronic hypersensitivity pneumonitis patients. Pulm Pharmacol Ther 2020;60:101878.
  56. Vorselaars AD, Wuyts WA, Vorselaars VM, Zanen P, Deneer VH, Veltkamp M, et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest 2013;144:805-12. https://doi.org/10.1378/chest.12-1728
  57. Corte TJ, Ellis R, Renzoni EA, Hansell DM, Nicholson AG, du Bois RM, et al. Use of intravenous cyclophosphamide in known or suspected, advanced non-specific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2009;26:132-8.
  58. Duarte AC, Cordeiro A, Fernandes BM, Bernardes M, Martins P, Cordeiro I, et al. Rituximab in connective tissue disease-associated interstitial lung disease. Clin Rheumatol 2019;38:2001-9. https://doi.org/10.1007/s10067-019-04557-7
  59. Maher TM, Tudor VA, Saunders P, Gibbons MA, Fletcher SV, Denton CP, et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med 2023;11:45-54. https://doi.org/10.1016/S2213-2600(22)00359-9
  60. Mankikian J, Caille A, Reynaud-Gaubert M, Agier MS, Bermudez J, Bonniaud P, et al. Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial. Eur Respir J 2023;61:2202071.
  61. Johannson KA, Chaudhuri N, Adegunsoye A, Wolters PJ. Treatment of fibrotic interstitial lung disease: current approaches and future directions. Lancet 2021;398:1450-60. https://doi.org/10.1016/S0140-6736(21)01826-2
  62. Khanna D, Lin CJ, Furst DE, Goldin J, Kim G, Kuwana M, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 2020;8:963-74. https://doi.org/10.1016/S2213-2600(20)30318-0
  63. Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 2016;387:2630-40. https://doi.org/10.1016/S0140-6736(16)00232-4
  64. Manfredi A, Cassone G, Furini F, Gremese E, Venerito V, Atzeni F, et al. Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study. Intern Med J 2020;50:1085-90. https://doi.org/10.1111/imj.14670
  65. Jacobs SS, Krishnan JA, Lederer DJ, Ghazipura M, Hossain T, Tan AM, et al. Home oxygen therapy for adults with chronic lung disease: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 2020;202:e121-41. https://doi.org/10.1164/rccm.202009-3608ST
  66. Johannson KA, Pendharkar SR, Mathison K, Fell CD, Guenette JA, Kalluri M, et al. Supplemental oxygen in interstitial lung disease: an art in need of science. Ann Am Thorac Soc 2017;14:1373-7. https://doi.org/10.1513/AnnalsATS.201702-137OI
  67. Bolton CE, Bevan-Smith EF, Blakey JD, Crowe P, Elkin SL, Garrod R, et al. British Thoracic Society guideline on pulmonary rehabilitation in adults. Thorax 2013;68 Suppl 2:ii1-30. https://doi.org/10.1136/thoraxjnl-2013-203808
  68. Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013;188:e13-64. https://doi.org/10.1164/rccm.201309-1634ST
  69. Dowman L, Hill CJ, May A, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev 2021;2:CD006322.
  70. Guler SA, Hur SA, Stickland MK, Brun P, Bovet L, Holland AE, et al. Survival after inpatient or outpatient pulmonary rehabilitation in patients with fibrotic interstitial lung disease: a multicentre retrospective cohort study. Thorax 2022;77:589-95. https://doi.org/10.1136/thoraxjnl-2021-217361
  71. Mendes RG, Castello-Simoes V, Trimer R, Garcia-Araujo AS, Goncalves Da Silva AL, Dixit S, et al. Exercise-based pulmonary rehabilitation for interstitial lung diseases: a review of components, prescription, efficacy, and safety. Front Rehabil Sci 2021;2:744102.
  72. Kapnadak SG, Raghu G. Lung transplantation for interstitial lung disease. Eur Respir Rev 2021;30:210017.
  73. Leard LE, Holm AM, Valapour M, Glanville AR, Attawar S, Aversa M, et al. Consensus document for the selection of lung transplant candidates: an update from the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2021;40:1349-79. https://doi.org/10.1016/j.healun.2021.07.005
  74. Park JE, Kim SY, Song JH, Kim YS, Chang J, Lee JG, et al. Comparison of short-term outcomes for connective tissue disease-related interstitial lung disease and idiopathic pulmonary fibrosis after lung transplantation. J Thorac Dis 2018;10:1538-47. https://doi.org/10.21037/jtd.2018.02.50
  75. Yazdani A, Singer LG, Strand V, Gelber AC, Williams L, Mittoo S. Survival and quality of life in rheumatoid arthritis-associated interstitial lung disease after lung transplantation. J Heart Lung Transplant 2014;33:514-20.  https://doi.org/10.1016/j.healun.2014.01.858